Name: Name:4-Phenylamino-6,7-dimethoxyquinazoline
Brand: AABLOCKS
SKU: AA007PVD
Rating: 90 (10 reviews)

Catalog No.: AA007PVD

21561-09-1 | 4-Phenylamino-6,7-dimethoxyquinazoline

Pack Size： 1mg

Purity： 98% by HPLC

in stock

$88.00 $61.00

Pack Size： 5mg

Purity： ≥98%

in stock

$106.00 $74.00

Pack Size： 10mg

Purity： ≥98%

in stock

$169.00 $118.00

Pack Size： 25mg

Purity： ≥98%

in stock

$289.00 $202.00

Quantity

- +

Add to Card

Order Now

bulk Quotation Request

Technical Information

Catalog Number: AA007PVD

Chemical Name: 4-Phenylamino-6,7-dimethoxyquinazoline

CAS Number: 21561-09-1

Molecular Formula: C16H15N3O2

Molecular Weight: 281.3092

MDL Number: MFCD01815294

SMILES: COc1cc2c(ncnc2cc1OC)Nc1ccccc1

Properties

Complexity: 323

Covalently-Bonded Unit Count: 1

Defined Atom Stereocenter Count: 0

Defined Bond Stereocenter Count: 0

Formal Charge: 0

Heavy Atom Count: 21

Hydrogen Bond Acceptor Count: 5

Hydrogen Bond Donor Count: 1

Isotope Atom Count: 0

Rotatable Bond Count: 4

Undefined Atom Stereocenter Count: 0

Undefined Bond Stereocenter Count: 0

XLogP3: 3.4

Downstream Synthesis Route

62-53-3

13790-39-1

21561-09-1

[1]BioorganicandMedicinalChemistryLetters,2011,vol.21,p.1371-1375

[2]JournalofMedicinalChemistry,2019,vol.62,p.2428-2446

[3]OrganicLetters,2019,vol.21,p.5111-5115

[4]BioorganicandMedicinalChemistry,2014,vol.22,p.1909-1915

[5]BioorganicandMedicinalChemistry,1996,vol.4,p.1203-1207

[6]BioorganicandMedicinalChemistryLetters,2016,vol.26,p.2724-2729

[7]Molecules,2021,vol.26

100-52-7

21561-09-1

6,7-dimethoxy-8-(hydroxyphenylmethyl)-4-phenylaminoquinazoline

[1]Chapoulaud,V.Gautheron;Salliot;Ple;Turck;Queguiner[Tetrahedron,1999,vol.55,#17,p.5389-5404]

75-07-0

21561-09-1

6,7-dimethoxy-8-(1-hydroxyethyl)-4-phenylaminoquinazoline

[1]Chapoulaud,V.Gautheron;Salliot;Ple;Turck;Queguiner[Tetrahedron,1999,vol.55,#17,p.5389-5404]

5653-40-7

21561-09-1

[1]Gazit,Aviv;Chen,Jeffrey;Harald,App;McMahon,Gerald;Hirth,Peter;Chen,Irit;Levitzki,Alexander[BioorganicandMedicinalChemistry,1996,vol.4,#8,p.1203-1207]

[2]Bensinger,Dennis;Stubba,Daniel;Cremer,Anjali;Kohl,Vanessa;Waßmer,Theresa;Stuckert,Johanna;Engemann,Victoria;Stegmaier,Kimberly;Schmitz,Katja;Schmidt,Boris[JournalofMedicinalChemistry,2019,vol.62,#5,p.2428-2446]

Literature fold

Title: Synthesis and structure-activity relationships of (aryloxy)quinazoline ureas as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors.

Journal: Journal of medicinal chemistry20120209

Title: Investigation of a novel molecular descriptor for the lead optimization of 4-aminoquinazolines as vascular endothelial growth factor receptor-2 inhibitors: application for quantitative structure-activity relationship analysis in lead optimization.

Journal: Bioorganic & medicinal chemistry letters20110301

Title: Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.

Journal: Bioorganic & medicinal chemistry letters20101101

Title: Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor.

Journal: Journal of medicinal chemistry19960105

Title: Sudbeck EA, et al. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin Cancer Res. 1999 Jun;5(6):1569-82.

Title: Tibbles HE, et al. Role of a JAK3-dependent biochemical signaling pathway in platelet activation and aggregation. J Biol Chem. 2001 May 25;276(21):17815-22.